These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15362927)

  • 21. New and emerging therapies for sepsis.
    Healy DP
    Ann Pharmacother; 2002 Apr; 36(4):648-54. PubMed ID: 11918516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of drotrecogin alfa (activated) in older patients with severe sepsis.
    Alexander SL; Ernst FR
    Pharmacotherapy; 2006 Apr; 26(4):533-8. PubMed ID: 16553513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
    van Heesch MM; van Asselt AD; Evers JL; van der Hoeven MA; Dumoulin JC; van Beijsterveldt CE; Bonsel GJ; Dykgraaf RH; van Goudoever JB; Koopman-Esseboom C; Nelen WL; Steiner K; Tamminga P; Tonch N; Torrance HL; Dirksen CD
    Hum Reprod; 2016 Nov; 31(11):2527-2540. PubMed ID: 27907897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
    Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
    Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activated protein C for severe sepsis.
    Garces K
    Issues Emerg Health Technol; 2002 Mar; (30):1-4. PubMed ID: 11985365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Activated protein C, coagulation, inflammation and treatment of severe sepsis].
    Ott A
    Ned Tijdschr Geneeskd; 2001 Nov; 145(45):2196-7. PubMed ID: 11727624
    [No Abstract]   [Full Text] [Related]  

  • 28. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacotherapy of sepsis].
    Guzzo I; Morabito S; Stucchi R; Poli G; Fumagalli R
    G Ital Nefrol; 2006; 23 Suppl 36():S79-86. PubMed ID: 17068734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of drotrecogin alfa (activated).
    Tsitanidis J
    Crit Care Med; 2003 Sep; 31(9):2414-5; author reply 2415. PubMed ID: 14501983
    [No Abstract]   [Full Text] [Related]  

  • 31. Recombinant human activated protein C for use in severe sepsis.
    Bearden DT; Garvin CG
    Ann Pharmacother; 2002 Sep; 36(9):1424-9. PubMed ID: 12196063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Principles of pharmacoeconomic analysis of drug therapy.
    Freund DA; Dittus RS
    Pharmacoeconomics; 1992 Jan; 1(1):20-31. PubMed ID: 10147037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in sepsis therapy.
    Glück T; Opal SM
    Drugs; 2004; 64(8):837-59. PubMed ID: 15059039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drotrecogin alfa (activated).
    Lyseng-Williamson KA; Perry CM
    Drugs; 2002; 62(4):617-30; discussion 631-2. PubMed ID: 11893230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammation and coagulation: implications for the septic patient.
    Dellinger RP
    Clin Infect Dis; 2003 May; 36(10):1259-65. PubMed ID: 12746771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations.
    Balk RA
    Dis Mon; 2004 Apr; 50(4):168-213. PubMed ID: 15133467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacoeconomics of available treatment options for metastatic prostate cancer.
    Zeliadt SB; Penson DF
    Pharmacoeconomics; 2007; 25(4):309-27. PubMed ID: 17402804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economics and outcome in the intensive care unit.
    Pittoni GM; Scatto A
    Curr Opin Anaesthesiol; 2009 Apr; 22(2):232-6. PubMed ID: 19390250
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.